Semaglutide Side Effects by Dose: What the Trial Data Actually Shows

Most semaglutide side effect lists are undifferentiated. Nausea, vomiting, diarrhoea, constipation, in a bullet list, with no indication of how often any of it happens or whether the dose makes a difference. It does make a difference, and the numbers are published. The FDA-approved prescribing information reports adverse reactions separately at each strength alongside placebo, which turns a vague list into something you can actually plan around.

This guide sets out those figures dose by dose for oral semaglutide, then covers the injectable data, the serious warnings, and the laboratory changes that show up without symptoms. Every number here comes from the approved labelling or a named trial.

Gastrointestinal reactions, dose by dose

The table below comes from a pool of two placebo-controlled trials covering 1,071 patients treated with oral semaglutide, with a mean exposure of 41.8 weeks. It lists every reaction reported in at least 5% of treated patients.

Adverse reaction	Placebo (n=362)	7 mg (n=356)	14 mg (n=356)
Nausea	6%	11%	20%
Abdominal pain	4%	10%	11%
Diarrhoea	4%	9%	10%
Decreased appetite	1%	6%	9%
Vomiting	3%	6%	8%
Constipation	2%	6%	5%

Nausea is the clearest dose-dependent effect: 6% on placebo, roughly doubling at 7 mg, and more than tripling at 14 mg. Constipation is the interesting outlier, at 6% on 7 mg and 5% on 14 mg, which means the higher dose did not make it worse in these trials.

Taking gastrointestinal reactions as a whole rather than individually, the rates were 21% on placebo, 32% on 7 mg and 41% on 14 mg. So roughly one in five people on placebo reported something gastrointestinal, against two in five at the top dose. Placebo rates that high are a reminder that not every symptom during treatment is caused by the drug.

Severity and discontinuation

Frequency is only half the picture. What matters more is how many people had to stop.

• Severe gastrointestinal reactions: 0.3% on placebo, 0.6% on 7 mg, 2.0% on 14 mg.
• Discontinued treatment because of gastrointestinal reactions: 1% on placebo, 4% on 7 mg, 8% on 14 mg.

So at the 14 mg dose, about two in five people report gastrointestinal symptoms, one in fifty reports something severe, and roughly one in twelve stops the medicine over it. That is the honest shape of the risk. Common, mostly tolerable, occasionally the reason treatment ends.

One detail from the label matters more than any of these percentages: the majority of nausea, vomiting and diarrhoea reports occurred during dose escalation. These are not permanent features of treatment. They cluster in the weeks after each step up and then largely settle. That is the entire rationale for the 30-day titration blocks described in our oral semaglutide dosing guide, and it is why pushing to the next dose early tends to backfire.

Less common gastrointestinal effects

Below the 5% threshold, the label lists these, given as 14 mg, 7 mg, then placebo:

• Abdominal distension: 3%, 2%, 1%
• Gastro-oesophageal reflux disease: 2%, 2%, 0.3%
• Gastritis: 2%, 2%, 0.8%
• Eructation: 2%, 0.6%, 0%
• Flatulence: 1%, 2%, 0%
• Dyspepsia: 0.6%, 3%, 0.6%

The boxed warning

Semaglutide carries a boxed warning for thyroid C-cell tumours. In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumours at clinically relevant exposures. Whether this happens in humans is not known, because the human relevance of the rodent finding has not been determined.

The regulatory response is a hard contraindication rather than a caution. Semaglutide must not be used by anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. The label also notes that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection in treated patients, which is a candid admission that there is no reliable screening approach. Symptoms to report are a neck mass, difficulty swallowing, shortness of breath and persistent hoarseness.

Serious reactions with real numbers behind them

Pancreatitis. In the pooled placebo and active-controlled oral semaglutide trials, pancreatitis was reported as a serious adverse event in 6 treated patients, at 0.1 events per 100 patient-years, against 1 comparator-treated patient at under 0.1 events per 100 patient-years. Rare, but the reason persistent severe abdominal pain, sometimes radiating to the back and often with vomiting, is a stop-and-call-someone symptom rather than a wait-and-see one.

Gallbladder disease. Cholelithiasis was reported in 1% of patients on 7 mg. It was not reported at 14 mg or on placebo in those trials. A published safety review concluded that semaglutide increases the risk of biliary disease, with rapid weight reduction being a plausible contributor.

Diabetic retinopathy. Retinopathy-related adverse reactions were reported in 4.2% of oral semaglutide patients against 3.8% of comparator patients. The mechanism is thought to involve rapid improvement in glucose control rather than the drug itself, which is why anyone with existing retinopathy warrants closer eye monitoring when starting.

Acute kidney injury. There are postmarketing reports of acute kidney injury and worsening chronic renal failure, some requiring dialysis. The majority occurred in people who had become volume depleted through nausea, vomiting or diarrhoea. This makes the kidney risk downstream of the gastrointestinal effects, which in turn makes fluid intake during a bad episode a genuine safety matter rather than general advice.

Hypoglycaemia with other diabetes medicines. Semaglutide alone carries a low hypoglycaemia risk because it stimulates insulin release only when glucose is elevated. Combined with a sulfonylurea such as glimepiride or with insulin, the risk rises, including severe hypoglycaemia, and the label advises considering a reduction in the sulfonylurea or insulin dose when semaglutide is started. Our comparison of metformin and glimepiride covers how these classes differ on this point.

Pulmonary aspiration during anaesthesia. This is a more recent addition to the warnings. Because semaglutide delays gastric emptying, food may remain in the stomach longer than expected before general anaesthesia or deep sedation. Anyone on semaglutide who is scheduled for a procedure should tell both the surgeon and the anaesthetist, and should not assume standard fasting instructions are sufficient.

Oral semaglutide is also not recommended in severe gastroparesis, which follows from the same mechanism.

Laboratory and vital sign changes without symptoms

Some effects show up only in bloodwork.

• Amylase and lipase. Mean increases from baseline of 10% amylase and 30% lipase on 7 mg, and 13% amylase and 34% lipase on 14 mg. Neither was seen on placebo. With the injectable, the mean increases were larger at 16% amylase and 39% lipase. The label states plainly that the clinical significance of these elevations is unknown in the absence of other signs of pancreatitis, which is worth knowing before an isolated raised lipase result causes alarm.
• Heart rate. A mean increase of 1 to 3 beats per minute on 7 mg and 14 mg, with no change on placebo.

The injectable side effect profile

Injectable semaglutide used for chronic weight management reaches higher exposures than the oral tablets, and the tolerability figures reflect that.

• Severe gastrointestinal reactions: 4.1% on the injection against 0.9% on placebo. For comparison, the oral tablet used for weight management reported 2% against 0% on placebo.
• Permanent discontinuation due to a gastrointestinal reaction: 4.3% against 0.7% on placebo.
• Injection site reactions: 1.4% against 1.0% on placebo, which is barely above background.

A meta-analysis of four randomised trials covering 3,613 people with obesity and without diabetes quantified the trade-off directly. Gastrointestinal adverse events were 1.59 times more likely on semaglutide, discontinuation due to adverse events was 2.19 times more likely, and serious adverse events were 1.60 times more likely, against a mean weight difference of 11.85 percentage points favouring semaglutide.

As with the tablets, these reactions were most frequently reported during dose escalation, and the label explicitly allows delaying a step by four weeks rather than pushing through poor tolerance. Our range covers the full escalation ladder from the Wegovy 0.25mg FlexTouch pen to the 2.40mg maintenance pen.

What happens after stopping

This is not a side effect in the labelling sense, but it is the single most under-discussed part of semaglutide treatment, and the data is unambiguous.

The STEP 1 trial extension followed 327 participants for a year after treatment stopped. During the 68 weeks of treatment, mean weight loss was 17.3% on semaglutide against 2.0% on placebo. In the year after withdrawal, the semaglutide group regained 11.6 percentage points of the weight they had lost, ending at a net 5.6% below their starting weight at week 120. The cardiometabolic improvements seen during treatment also moved back toward baseline.

For contrast, the STEP 5 trial showed that with treatment continued, mean weight change at two years was 15.2% against 2.6% on placebo, with 77.1% of the semaglutide group achieving at least 5% loss against 34.4% on placebo.

Read together, these two results make the same point from opposite directions. The effect is substantial and it persists while treatment persists. Stopping is not a neutral event, and anyone considering it should be planning that conversation with a prescriber rather than simply not renewing.

Putting the risk in proportion

A published safety review covering the full SUSTAIN and PIONEER programmes concluded that semaglutide causes mostly mild to moderate and transient gastrointestinal disturbance, increases the risk of biliary disease, and that no unexpected safety issues have emerged to date.

That summary is consistent with the tables above. The common effects are gastrointestinal, dose-related, concentrated around escalation, and usually manageable. The rare effects are serious enough to justify a boxed warning and a set of hard contraindications. The gap between those two categories is where a prescriber earns their fee, because deciding whether a given person should take this drug depends on thyroid history, pancreatic history, kidney function, eye status and what else they are already taking. Our type 2 diabetes treatment overview sets out where GLP-1 receptor agonists sit relative to the other drug classes.

Medical disclaimer

This article is educational and does not replace advice from a qualified healthcare professional. Semaglutide requires a prescription in the United States, United Kingdom, Canada and Australia, and is prescribed under supervision for defined medical indications. Do not start, stop or change semaglutide, or any medicine taken alongside it, without speaking to your prescriber. Seek prompt medical attention for persistent severe abdominal pain, signs of an allergic reaction, or symptoms of a thyroid lump. Tell your surgeon and anaesthetist about semaglutide before any procedure involving general anaesthesia or deep sedation.

References

• FDA-approved prescribing information for RYBELSUS and OZEMPIC (semaglutide) tablets, Boxed Warning, section 5 Warnings and Precautions, and section 6.1 Adverse Reactions including Table 2.
• FDA-approved prescribing information for WEGOVY (semaglutide) injection, section 5 Warnings and Precautions and section 6.1 Adverse Reactions.
• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. PubMed PMID: 35441470.
• Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. PubMed PMID: 36216945.
• Tan HC et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. PubMed PMID: 36578889.
• Smits MM, Van Raalte DH. Safety of Semaglutide. PubMed PMID: 34305810.